SAB Biotherapeutics SABS
NASDAQ SABS
$2.82 -0.06 (-2.08%)
At close: Oct 21, 2026 · 4:00 PM EDT

SAB Biotherapeutics (SABS) EV to CFO (2021)

Updated

SAB Biotherapeutics' EV to CFO came in at 90.75 for Q4 2021, up 349.6% from the prior quarter.

Analysis

SAB Biotherapeutics (SABS) EV to CFO (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 SAB Biotherapeutics 223.71 Mn -193.79 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 90.75
Sep 30, 2021 20.18
API Access

SAB Biotherapeutics EV to CFO API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=SABS&period=max&api_key=YOUR_API_KEY